AI Targets Tumors; Preventing Postpartum Risks; and More

A combined approach of crowd innovation and artificial intelligence (AI) algorithms can rapidly produce tumor targeting results for radiation oncologists, according to a study published in JAMA Oncology.

Routine regional lymphadenectomy should be considered for patients with pancreatic neuroendocrine tumors (PanNETS), according to the findings of study published in Annals of Surgical Oncology.

In other oncology news, a novel aptamer (Apt63), was found to serve as a unique tool for potentially predicting and treating metastatic breast and prostate cancer, according a study published in Breast Cancer Research and Treatment.

In opioid-related news, researchers of a Frontiers in Chemistry published study developed a new method for detecting the newest fentanyl analogs, which can be used by clinical and forensic toxicologists as a documenting tool.

A study published in Preventing Chronic Disease demonstrated the importance of the postpartum year as a opportunity to mitigate future risk of diabetes and cardiovascular disease in women with a history of gestational diabetes mellitus.

Finally, in a wrap-up of several sessions presented at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference: oncology physicians should heed self-care steps that could prevent against developing burnout, while Brentuximab Vedotin (BV) was found to be safe and effective in patients with advanced stage Hodgkin’s Lymphoma. Moreover, the drug Sunitnib showed efficacy in individuals categorized with favorable risk Renal Cell Carcinoma, and new advances in treatment options for Chronic Lymphocytic Leukemia (CLL) were examined.